X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA CIPLA NATCO PHARMA/
CIPLA
 
P/E (TTM) x 30.4 43.7 69.5% View Chart
P/BV x 23.0 3.8 603.3% View Chart
Dividend Yield % 0.5 0.3 147.7%  

Financials

 NATCO PHARMA   CIPLA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
CIPLA
Mar-17
NATCO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs877622 141.0%   
Low Rs424458 92.4%   
Sales per share (Unadj.) Rs223.4181.9 122.9%  
Earnings per share (Unadj.) Rs31.112.9 241.4%  
Cash flow per share (Unadj.) Rs40.329.3 137.4%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.80.4 207.7%  
Book value per share (Unadj.) Rs219.5155.7 141.0%  
Shares outstanding (eoy) m33.07804.51 4.1%   
Bonus/Rights/Conversions PAESOP-  
Price / Sales ratio x2.93.0 98.0%   
Avg P/E ratio x20.942.0 49.9%  
P/CF ratio (eoy) x16.118.4 87.6%  
Price / Book Value ratio x3.03.5 85.4%  
Dividend payout %16.115.5 103.6%   
Avg Mkt Cap Rs m21,504434,516 4.9%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m1,12826,338 4.3%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m7,389146,302 5.1%  
Other income Rs m1672,287 7.3%   
Total revenues Rs m7,556148,589 5.1%   
Gross profit Rs m1,79324,758 7.2%  
Depreciation Rs m30413,229 2.3%   
Interest Rs m3661,594 23.0%   
Profit before tax Rs m1,29012,222 10.6%   
Minority Interest Rs m460-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3091,798 17.2%   
Profit after tax Rs m1,02710,354 9.9%  
Gross profit margin %24.316.9 143.4%  
Effective tax rate %23.914.7 162.7%   
Net profit margin %13.97.1 196.5%  
BALANCE SHEET DATA
Current assets Rs m3,68187,370 4.2%   
Current liabilities Rs m3,12333,081 9.4%   
Net working cap to sales %7.637.1 20.4%  
Current ratio x1.22.6 44.6%  
Inventory Days Days8987 102.9%  
Debtors Days Days5962 94.2%  
Net fixed assets Rs m7,685111,567 6.9%   
Share capital Rs m3311,609 20.6%   
"Free" reserves Rs m6,670123,645 5.4%   
Net worth Rs m7,259125,254 5.8%   
Long term debt Rs m95536,454 2.6%   
Total assets Rs m11,957209,532 5.7%  
Interest coverage x4.58.7 52.2%   
Debt to equity ratio x0.10.3 45.2%  
Sales to assets ratio x0.60.7 88.5%   
Return on assets %11.75.7 204.4%  
Return on equity %14.28.3 171.2%  
Return on capital %20.78.5 243.8%  
Exports to sales %39.434.2 115.0%   
Imports to sales %5.78.3 68.3%   
Exports (fob) Rs m2,90850,050 5.8%   
Imports (cif) Rs m42112,203 3.5%   
Fx inflow Rs m3,44551,066 6.7%   
Fx outflow Rs m70317,678 4.0%   
Net fx Rs m2,74333,388 8.2%   
CASH FLOW
From Operations Rs m1,44023,824 6.0%  
From Investments Rs m-1,089-13,127 8.3%  
From Financial Activity Rs m-353-13,239 2.7%  
Net Cashflow Rs m-1-2,478 0.1%  

Share Holding

Indian Promoters % 52.0 16.0 325.3%  
Foreign collaborators % 1.5 20.8 7.1%  
Indian inst/Mut Fund % 7.8 12.2 64.3%  
FIIs % 16.6 23.7 70.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 26.0 26.2 99.2%  
Shareholders   25,395 161,166 15.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   WYETH LTD  PFIZER  ALKEM LABORATORIES  AJANTA PHARMA  FULFORD INDIA  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Positive Note; Apollo Micro Systems IPO Lists at 74% Premium(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the energy sector and IT sector witnessing maximum buying interest.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jan 22, 2018 01:39 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS